How Superdrol (Methyldrostanolone) Affects ALT

Superdrol (methyldrostanolone, methasterone) is a 17-alpha-alkylated oral steroid with extreme hepatotoxic potential:

1. Potent C17-aa structure: Superdrol combines 17-alpha-alkylation with a 2a,17a-dimethyl structure that makes it exceptionally resistant to hepatic metabolism. This means the liver is exposed to very high concentrations of active compound for prolonged periods.
2. Severe cholestatic injury: Superdrol is notorious for causing intrahepatic cholestasis. It aggressively impairs bile salt transport proteins, causing bile acid accumulation that damages hepatocytes through detergent-like cytotoxicity.
3. Hepatocellular necrosis: The degree of hepatocyte destruction caused by superdrol is among the highest of any commonly used oral steroid. Massive ALT and AST release reflects genuine liver cell death, not merely membrane leakiness.
4. Ductular reaction: Prolonged superdrol use can trigger ductular proliferation and inflammation (cholangitis), a more serious form of liver injury that takes longer to resolve.

Superdrol achieved notoriety because it was marketed as a "prohormone" and sold legally in the United States until 2012, leading many users to underestimate its toxicity. Case reports of hospitalisations for cholestatic jaundice from superdrol are well-documented in the medical literature.

Low doses (10 mg/day):

• ALT commonly rises 5-10x ULN (200-400 U/L) within 2-3 weeks
• Even at this "low" dose, some individuals develop significant cholestasis
• Bilirubin may begin rising by week 2-3

Standard doses (20-30 mg/day):

• ALT frequently reaches 10-30x ULN (400-1200+ U/L)
• AST rises proportionally
• Direct bilirubin elevation is common, causing visible jaundice in some users
• GGT and ALP rise significantly, reflecting cholestatic injury pattern

Timeline: Superdrol's hepatotoxicity is notable for its rapid onset. Significant ALT elevation can occur within 7-10 days. Peak values are typically seen at weeks 2-4, which is why cycles rarely exceed 3-4 weeks.

Cholestatic jaundice: Multiple case reports describe users developing clinical jaundice (bilirubin above 5 mg/dL) within 2-4 weeks of starting superdrol. Recovery from cholestatic jaundice can take 2-3 months.

Pre-cycle: Comprehensive liver panel is mandatory. Do not use superdrol with any baseline liver abnormality.

On cycle: Check liver enzymes at day 10-14. This is not optional. Superdrol can cause dangerous elevations faster than almost any other oral steroid.

Second check: If continuing beyond 2 weeks, recheck at day 21.

Post-cycle: Check at 2 weeks and 6 weeks post-discontinuation. Cholestatic injury from superdrol can take 6-12 weeks to fully resolve.

Immediate cessation required if:

• ALT exceeds 10x ULN at any point
• Any bilirubin elevation above normal
• Dark urine, pale/clay-coloured stools, or itching (pruritis, a sign of cholestasis)
• Jaundice (yellowing of eyes or skin)
• Severe fatigue, nausea, or loss of appetite

Medical referral: If ALT exceeds 20x ULN or bilirubin exceeds 3 mg/dL, emergency medical evaluation is recommended. These levels indicate serious hepatic injury.

Liver support (absolutely essential):

• TUDCA 1500-2000 mg/day (high dose, non-negotiable with superdrol)
• NAC 1200-1800 mg/day
• Milk thistle 1000 mg/day
• Some users add injectable glutathione during superdrol cycles

Cycle design:

• Maximum 3 weeks; 4 weeks is the absolute upper limit, and many experienced users cap it at 2-3 weeks
• 10-20 mg/day is the standard dose range; going above 20 mg dramatically increases hepatotoxicity without proportional benefit
• Never stack with any other C17-aa oral steroid
• Allow a minimum of 12 weeks of liver recovery before any subsequent oral steroid use

Risk reduction:

• Complete alcohol avoidance during and for 6 weeks after the cycle
• Avoid all hepatotoxic substances including acetaminophen and NSAIDs
• Robust hydration to support bile flow
• Pre-loading TUDCA for 3-5 days before starting superdrol may provide additional protection

If severe hepatotoxicity occurs (ALT above 10x ULN):

• Discontinue immediately; do not attempt to "push through"
• Continue maximum-dose TUDCA and NAC
• Seek medical evaluation; severe superdrol-induced cholestasis may require inpatient monitoring
• Recovery typically takes 4-12 weeks depending on severity